Free shipping on all orders over $ 500

VEGFR/PDGFR Vascular Endothelial Growth Factor Receptor/platelet-derived growth factor receptor

Inhibitors

Cat.No.  Name Information
M1658 Axitinib Axitinib (AG013736) inhibits multiple targets including VEGFR, PDGFR and cKit.
M2194 SU5402 SU5402 is a potent and selective VEGFR and FGFR inhibitor with IC50 values of 0.02, 0.03, 0.51 and > 100 μM for VEGFR2, FGFR1, PDGFRβ and EGFR respectively.
M1838 Masitinib Masitinib is a tyrosine kinase inhibitor targeting stem cell factor receptor (c-kit) and platelet-derived growth factor (PDGF) receptor.
M1956 Apatinib mesylate Apatinib is a small-molecule multitargeted tyrosine kinase inhibitor of VEGFR2 with an IC50 of 2.43 nM.
M1841 Lenvatinib Lenvatinib (E7080) is a potent inhibitor of multiple tyrosine kinases, including VEGF-R3 tyrosine kinase (IC50=5.2 nM) and VEGF-R2 tyrosine kinase (IC50=4.0 nM).
M11224 Pamufetinib Pamufetinib (TAS-115) is a highly potent inhibitor of both C-MET and VEGFR, with IC50 of 30 nM and 32 nM against recombinant VEGFR2 and VEGFR, respectively.
M10945 Chiauranib Chiauranib (CS2164) is a multi-target inhibitor with oral activity against tumor angiogenesis. Chiauranib effectively inhibits angiogenesis-associated kinases (VEGFR1, VEGFR2, VEGFR3, PDGFRα and c-Kit), mitosis-associated kinase Aurora B, and chronic inflammation-associated kinase CSF-1R,IC50 The value is 1-9 nM. Chiauranib has a strong anti-cancer effect.
M10511 TAS-115 mesylate TAS-115 (Pamufetinib) mesylate inhibited the kinase activity of both VEGFR2 and MET and their signal-dependent cell growth as strongly as other known VEGFR or MET inhibitors.
M10329 Ningetinib Ningetinib is a potent, orally bioavailable tyrosine kinase inhibitor for Axl, VEGFR2 and c-Met with IC50 values of <1.0, 1.9 and 6.7 nM, respectively.
M9873 Tanshinone IIA Tanshinone IIA suppresses angiogenesis by targeting the protein kinase domains of VEGF/VEGFR2. *The compound is unstable in solutions, freshly prepared is recommended.
M9757 AC710 AC710 is a potent, selective and orally active platelet-derived growth factor receptor-family (PDGFR) kinase inhibitor with potential anticancer activity.
M9626 Sitravatinib Sitravatinib (MGCD516) is an orally active receptor tyrosine kinase (RTK) inhibitor. Inhibition of Axl, MER, VEGFR3, VEGFR2, VEGFR1, KIT, FLT3, DDR2, DDR1, TRKA, and TRKB at 1.5 nM, 2 nM, 2 nM, 5 nM, 6 nM, 6 nM, 8 nM, 0.5 nM, respectively. 29 nM, 5 nM and 9 nM. Sitravatinib alone has a potent antitumor effect and enhances pD-1 blockade activity by promoting the antitumor immune microenvironment.
M9540 ODM-203 ODM-203 is an orally available inhibitor of VEGFR and FGFR, with IC50s of 26, 9, 5 nM for VEGFR1, VEGFR2 and VEGFR3, and 11, 16, 6, 35 nM for recombinant FGFR1, FGFR2, FGFR3 and FGFR4, respectively.
M9465 MAZ51 MAZ51 is originally synthesized inhibitor of VEGFR-3 (Flt-4) tyrosine kinase, inhibits VEGF-C-induced activation of VEGFR-3 without blocking VEGF-C-mediated stimulation of VEGFR2.
M9429 SU14813 SU14813 is a novel multiple receptor tyrosine kinase inhibitor with IC50s of 2, 50, 4, 15 nM for VEGFR-1, VEGFR-2, PDGFR-β and KIT.
M9285 SU 5205 SU 5205 is a VEGFR2 inhibitor with IC50 of 9.6 μM.
M9284 SU-5408 SU-5408 is a potent, cell-permeable inhibitor of mouse VEGFR2 kinase with IC50 of 70 nM.
M9283 SU 5214 SU 5214 is a modulator of tyrosine kinase signal transduction.
M9249 BFH772 BFH772 is a potent and selective VEGFR2 inhibitor with an IC50 value of 3 nM.
M9236 Ranibizumab Ranibizumab is a monoclonal antibody that inhibits angiogenesis by inhibiting Vascular endothelial growth factor A.
M9161 NVP-ACC789 NVP-ACC789 is an inhibitor of human VEGFR-1, VEGFR-2 (mouse VEGFR-2), VEGFR-3 and PDGFR-β with IC50s of 0.38, 0.02 (0.23), 0.18, 1.4 μM, respectively.
M9094 EG00229 Trifluoroacetate salt EG00229 Trifluoroacetate is the first small molecule inhibitor of the neuropilin-1 and VEGF-A interaction with an IC50 of inhibition of 8 uM (125I-VEGF binding to PAE/NRP1 cells).
M9073 Apatinib Apatinib is a selective VEGFR2 inhibitor with IC50 of 1 nM.
M8949 JI-101 JI-101 is an orally available multi-kinase inhibitor of VEGFR2,PDGFRβ and EphB4 with potential antiangiogenic and antineoplastic activities.
M8917 BAW2881 BAW2881 (NVP-BAW2881) is a potent and selective VEGFR2 inhibitor with activity to inhibit chronic and acute skin inflammation.



Contact Us

Products are for research use only. Not for human use. We do not sell to patients.
© Copyright 2010-2020 AbMole BioScience. All Rights Reserved.